Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients With High Risk Operable Prostate Cancer, to Assess the Efficacy and Toxicity of Cabazitaxel, and, to Explore Potential Predictive and Prognostic Markers of Clinical Outcome
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Cabazitaxel (Primary) ; Bicalutamide; Chlorphenamine; Dexamethasone; Goserelin; Leuprorelin; LHRH receptor modulators; Prednisolone; Ranitidine
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms CHROME
- 04 Jan 2021 Planned initiation date changed from 12 Nov 2020 to 15 Jan 2020.
- 12 Nov 2020 New trial record